Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Midwestern University
With
Northwestern University
BioCryst Pharmaceuticals
This study has been closed. No patients were enrolled as the peramivir EUA was rescinded.
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Patient is hospitalized and undergoing continuous renal replacement therapy (CRRT) as a result of the clinical management of the patient (i.e. CRRT is not initiated for the purpose of this study).
Patient is receiving peramivir for a positive rapid antigen test for influenza or on the basis of clinical suspicion with a high local epidemiological prevalence of H1N1 disease.
Patient has a CRRT blood flow rate greater than or equal to 100 mL/min with an ultrafiltrate +/- dialysis flow rate greater than or equal to 3000mL/hr,
The patient is anticipated to require CRRT and peramivir treatment for a full 24 hours (i.e. life expectancy is not less than 24 hours).
You may not be if
The patient has received greater than 5 doses of peramivir.
The subject has a pre-existing illness that, in the opinion of the investigator, would place the subject at an unreasonably increased risk through participation in this study.
The patient is receiving CRRT utilizing a pre-membrane dilution method.
Clareo Health | Pharmacokinetic Assessment of Peramivir in Hospitalized Adults Undergoing Continuous Renal Replacement Therapy
